Scarica l'app Stockscreener
4.95
2.17%
-0.11
Pre-mercato:
4.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$5.06
Aprire:
$5.05
Volume 24 ore:
283.90K
Relative Volume:
0.41
Capitalizzazione di mercato:
$274.33M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-2.2098
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
+10.99%
1M Prestazione:
-2.94%
6M Prestazione:
-47.78%
1 anno Prestazione:
-7.13%
Intervallo 1D:
$4.86
$5.19
Intervallo di 1 settimana:
$4.5135
$5.47
Portata 52W:
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.95 | 274.33M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa reports breakthrough in breast cancer treatment - Investing.com Australia
Monte Rosa reports breakthrough in breast cancer treatment By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewswire
Breakthrough: New Molecular Glue Degrader Achieves 77% Tumor Shrinkage in Hard-to-Treat Breast Cancer - Stock Titan
Monte Rosa Therapeutics Inc (GLUE) Sits And Waits For Direction At $5.06 Price - Stocksregister
Geode Capital Management LLC Lowers Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - uspostnews.com
Market Watch Highlights: Monte Rosa Therapeutics Inc (GLUE) Ends on an Upturn Note at 5.33 - DWinneX
GLUE’s 2023 Market Dance: Down -23.20% – Time to Invest? - investchronicle.com
How To Trade (GLUE) - news.stocktradersdaily.com
Monte Rosa Therapeutics Insider Ups Holding During Year - Yahoo Finance
Franklin Resources Inc. Buys Shares of 27,510 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Vanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Wellington Management Group LLP Grows Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
American Century Companies Inc. Has $533,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Sei Investments Co. Buys Shares of 17,236 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
How to Take Advantage of moves in (GLUE) - news.stocktradersdaily.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World
Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st
Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com India
Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World
Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha
FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World
Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey
Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks
Positive signs for Monte Rosa in early data - The Pharma Letter
Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga
Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Monte Rosa Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics sees cash runway into 2028 - TipRanks
Monte Rosa Therapeutics, Inc. SEC 10-K Report - TradingView
Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M - TipRanks
Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis - Endpoints News
Monte Rosa Therapeutics Reports Q4 2024 Financial Results - TipRanks
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):